Trials / Completed
CompletedNCT00462956
GW572016 In Patients With Advanced Or Metastatic Breast Cancer
Phase II Clinical Study of GW572016 in Patients With Advanced or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 20 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and safety of GW572016 in patients with refractory breast cancer and consists of two cohorts of patients. Patients in Cohort A must have ErbB2 overexpressing tumors while patients in Cohort B must have non-ErbB2 overexpressing tumors. Patients eligible for this study must have advanced metastatic breast cancer who have previously received treatment with anthracycline and taxane.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tykerb | lapatinib 1500mg daily |
Timeline
- Start date
- 2004-06-30
- Primary completion
- 2006-12-20
- Completion
- 2006-12-20
- First posted
- 2007-04-19
- Last updated
- 2018-08-31
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00462956. Inclusion in this directory is not an endorsement.